Archive


Category: Abbott

  • Abbott makes progress with wearable for diabetic ketoacidosis

    Abbott is already a big player in the wearable glucose-monitoring sector, and has started working on a new device that will measure both glucose and ketones, potentially serving as a warning system for a life-threatening complication of diabetes known as ketoacidosis. The system – which already has a breakthrough device designation from the FDA – […]

  • Abbott joins alliance to bring ‘artificial pancreas’ system to Europe

    Abbott has joined forces with two other companies to bring an automated insulin delivery (AID) system to people with diabetes in Europe that will monitor blood glucose levels and deliver insulin automatically. The three-way partnership brings Abbott’s FreeStyle Libre 3 wearable sensor with a mobile app developed by Camdiab that communicates with an insulin pump […]

  • Real-time Abbott glucose monitor available to NHS after UK launch

    The latest version of Abbott’s FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott’s wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user’s smartphone for […]

  • FDA expands use of Abbott’s heart sensor with new approval

    The FDA has approved expanded labelling for Abbott’s CardioMEMS HF System, an implantable sensor that provides an early warning of worsening heart failure, that could make it an option for more than a million more patients. The new approval makes the CardioMEMS device – which was first approved in the US in 2014 – an […]

  • Pharma’s digital inflection point

    Billed as the world’s most influential technology event, this year’s CES show saw its first ever keynote from a healthcare company when Abbott CEO Robert Ford took to the stage in Las Vegas last month. For Ford, the focus was on his company’s new range of consumer ‘biowearable’ health devices, but his appearance was also […]

  • Abbott CEO Ford showcases new ‘biowearable’ line at CES

    US medical device company Abbott has said it plans to launch a new range of ‘biowearable’ health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring. The company’s chief executive – Robert Ford – made the announcement at the massive CES tech trade show in Las Vegas, a venue […]

  • PharmaShots’ Key Highlights of Third Quarter 2021

    The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B, […]

  • PharmaShots Weekly Snapshots (September 20 – 24, 2021)

    Everest’s SPR206 Receives the NMPA’s IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections Published: Sept 24, 2021 | Tags: Everest, SPR206, NMPA, IND, Approval, MDR Gram-Negative Bacterial Infections GE Healthcare to Acquire BK Medical for ~ $1.45B Published: Sept 24, 2021 | Tags: GE Healthcare, Acquire, BK Medical, ~ $1.45B Roche Presents Results […]

  • Abbott’s Epic Plus Tissue Valves Receives the US FDA’s Approval for the Treatment of Mitral or Aortic Valve Replacement

    Shots: The US FDA has approved Abbott’s Epic Plus & Epic Plus Supra Stented Tissue valves to treat patients with aortic or MV disease who undergoes valve replacement surgery. The devices build off Abbott’s Epic surgical valve platform Abbott’s Epic valve including radiopaque markers helps to improve implantation & allows compatibility for future transcatheter valve […]

  • PharmaShots Weekly Snapshots (August 30 – September 03, 2021)

    Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis Published: Sept 3, 2021 | Tags: Novartis, Cosentyx, secukinumab, NICE Recommendation, Plaque Psoriasis Pfizer […]

  • PharmaShots Weekly Snapshots (August 30 – September 03, 2021)

    Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis Published: Sept 3, 2021 | Tags: Novartis, Cosentyx, secukinumab, NICE Recommendation, Plaque Psoriasis Pfizer […]

  • Abbott to Acquire Walk Vascular to Bolster its Peripheral Vascular Offerings

    Shots: The acquisition will accelerate Abbott’s vascular portfolio with the addition of Walk Vascular’s peripheral thrombectomy systems to treat patients with peripheral blood clots Walk Vascular’s JETi & JETi AIO peripheral thrombectomy systems are aspiration systems for the removal of intravascular clots. The systems are supported by RWE, and Walk is currently enrolling ~250 patients […]

  • Abbott Reports Head-to-Head Data for Amplatzer Amulet Against Boston Scientific’s Watchman Device to Treat Atrial Fibrillation #ESC2021

    Shots: The head-to-head Amulet IDE study compares Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with the Watchman device to treat patients with AFib at an increased risk of stroke The study demonstrated superiority for the 1EPs of LAA (98.9% vs 96.8%) and was non-inferior for the co-primary safety & effectiveness endpoints Abbott’s Amulet Occluder with […]

  • PharmaShots Weekly Snapshots (August 16 – 20, 2021)

    Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC Published: Aug 20, 2021 | Tags: Astellas, FibroGen, Evrenzo, Roxadustat, EC, Approval, Symptomatic Anemia, Chronic Kidney Disease Astellas and FibroGen’s Evrenzo (roxadustat) Receive EC’s Approval for Symptomatic Anemia Associated with Chronic Kidney Disease Published: Aug 20, 2021 […]

  • PharmaShots Weekly Snapshots (Aug 02 – 06, 2021)

    Medtronic to Acquire Intersect ENT for ~$1.1B Published: Aug 6, 2021 | Tags: Medtronic, Intersect ENT, ~$1.1B Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer Published: Aug 6, 2021 | Tags: Kite, Appia, Allogeneic Cell Therapies, Cancer Polpharma & Bioeq Report BLA Submission to the US […]

  • Abbott gets FDA clearance for CGM app

    Abbott received FDA clearance for an app to pair with its Freestyle Libre 2 glucose monitor. The app lets people get readings directly on their phone without using a reader.

  • Abbott bags FDA okay for AI-based heart imaging software

    The FDA has approved an artificial intelligence-based imaging software developed by Abbott that is used to help physicians carry out procedures like implanting stents to open up narrowed blood vessels in the heart.  Abbott‘s Ultreon software is billed as a first-of-its-kind platform that is designed to be used with optical coherence tomography (OCT), an imaging […]

  • Abbott Launches Jot Dx Insertable Cardiac Monitor to Detect Abnormal Heart Rhythms in US

    Shots: Abbott launches its latest Jot Dx ICM with new features to help clinicians for a constant flow of heart rhythm data to treat atrial fibrillation Jot Dx ICM allows 24/7 heart monitoring and connects directly with Abbott’s myMerlin smartphone app. The technology is designed to provide remote detection and improved diagnostic accuracy of cardiac […]

  • MedTech Wrap Up

    Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High-Frequency Nerve Block System On June 29, 2021, the US Food and Drug Administration (FDA) granted Neuros Medical, Inc. Breakthrough Device Designation for the use of their unique Altius High-Frequency Nerve Block device in the management of chronic intractable pain of the lower limb in […]

  • PharmaShots Weekly Snapshots (May 17 – 21, 2021)

    BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Published: May 21, 2021 | Tags: BeiGene, Tislelizumab, CT, P-III, RATIONALE 309 Study, Recurrent, Metastatic Nasopharyngeal Cancer Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR […]

  • Top 20 Medical Device Companies Based on 2020 Revenue

    The medical devices industry is a fast-growing market driven by the complex needs of patients encouraging life science companies to develop innovative therapies to improve health and QoL In 2020, the companies have shown growth resulted from a rise in the number of healthcare facilities, healthcare expenditure, technological advancements. Medtronic remains at the top of […]

  • ViewPoints Interview: Dr. Drew Falconer Shares Insights on the Abbott’s NeuroSphere Virtual Clinic

    In an interview with PharmaShots, Dr. Drew Falconer, Neurologist and Director at Inova Parkinson’s and Movement Disorders Center in Fairfax, Va. shares insights on the first neurostimulation technology in US that allows patients to receive treatment from doctor without leaving home. Shots: Abbott launches NeuroSphere Virtual Clinic that allows patients to communicate with their physicians, […]

  • Abbott Launches AI-Powered Coronary Imaging Platform in Europe

    Shots: Abbott’s new imaging platform powered by Ultreon 1.0 software has received a CE mark in the EU. The new imaging platform merges optical coherence tomography (OCT) with AI to enhance visualization and detect the severity of calcium-based blockages and measure vessel diameter Ultreon software when integrated with Abbott’s new Dragonfly OpStar imaging catheter allows […]

  • ViewPoints Interview: Abbott’s Allen Burton Shares Insight on NeuroSphere myPath App

    In an interview with PharmaShots, Allen Burton, M.D., Medical Director at Abbott Neuromodulation shared his views on the NeuroSphere myPath App which is designed to track and report pain relief in chronic pain patients. Shot: The app will record pain relief during the device trial period with SCS or DRG therapy, simplifying reporting outcomes & […]

  • PharmaShots Weekly Snapshots (Mar 08 – 12, 2021)

    PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab Published: Mar 12, 2021 | Tags: PhaseBio, Signs, Supply, Agreement, BioVectra, Support,  Development, Commercialization, Bentracimab Takeda Reports NDA Submission of Lanadelumab to the MHLW as a Preventive Treatment for Hereditary Angioedema Attack in Japan Published: Mar 12, 2021 | Tags: […]

  • Abbott Launches Pandemic Defense Coalition to Detect Future Threats

    Shots: The coalition builds on Abbott’s excellence in virus surveillance and aid in analyzing virus samples for unknown diseases and detects mutations and variants including COVID-19 The goal of the Pandemic Defense Coalition is to identify new pathogens, analyze potential risk level, assess public health impact in real-time, and contain outbreaks when new virus threats […]

  • Abbott Launches NeuroSphere Virtual Clinic for Remote Neurostim Programming in the US

    Shots: The US FDA has approved NeuroSphere Virtual Clinic that allows a patient to communicate with a physician and remotely receive stimulation settings in real time regardless of location NeuroSphere Virtual Clinic allows clinicians to provide new treatment settings remotely to the patient’s neurostimulation device using the clinician programmer app The virtual clinic is compatible […]

  • PharmaShots Weekly Snapshots (Jan 25- 29, 2021)

    Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development Published: Jan 29, 2020 | Tags: Roche, Collaborate, Cambridge Quantum Computing, Develop, Quantum Algorithm, Drug, Discovery, Development Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations Published: Jan 29, 2020 […]

  • Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening

    Shots: Abbott received a CE mark for asymptomatic testing and self-swabbing using its Panbio COVID-19 Ag test to detect SARS-CoV-2. Abbott has shipped 200M test to 120 countries globally The test is approved with a patient-friendly and minimally invasive nasal swab, i.e. patients can self-administer sample collection under an HCP’s supervision and delivers results in […]

  • Abbott to Launch App to Track and Report Pain Relief in Chronic Pain Patients

    What You Should Know: – Abbott launches new app, NeuroSphere myPath that will allow patients to record their pain relief during the device trial period with spinal cord stimulation or dorsal root ganglion therapy, simplify reporting outcomes and connect patients to physicians who have real-time access to this data – NeuroSphere myPath will be available […]

  • PharmaShots Weekly Snapshots (Jan 11 – 15, 2021)

    Novartis’ Ligelizumab (QGE031) Receives the US FDA’s Breakthrough Designation for Patients with Chronic Spontaneous Urticaria Published: Jan 15, 2020 | Tags: Novartis’, Ligelizumab (QGE031), Receives ,US FDA’s, Breakthrough Designation for Patients , Chronic Spontaneous Urticaria Philips Collaborates with Merck KGaA to Advance Personalized Fertility Treatment Published: Jan 15, 2020 | Tags: Philips, Collaborates, Merck KGaA, […]

  • PharmaShots Weekly Snapshots (Dec 14-18, 2020)

    Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada Published: Dec 17, 2020 | Tags: Authorization, Biosimilar, canada, health, Humira, Hyrimoz, Launch, receives, Sandoz Amgen’s Riabni (biosimilar, rituximab) Receives the US FDA’s Approval for Multiple Diseases Published: Dec 17, 2020 | Tags: Adult, Amgen, approval, Biosimilar, CLL, GPA, MPA, NHL, patients, receives, RIABNI, Rituxan, Rituximab, rituximab-arrx, […]

  • Why Some COVID-19 Testing Protocols Aren’t What You Think

    Pawel Czech, Founder of Nex.D While countries around the world continue to flounder with regards to COVID-19 testing, everyone is wondering how national governments could get things so horribly wrong. It’s true that governments have acted incompetently, leaders can make poor judgment calls, and optimistic testing targets are rarely achieved. But the claims of various […]

  • Abbott’s COVID-19 IgG Quantitative Antibody Blood Test Receives CE Mark

    Shots: Abbott received CE Mark for its new quantitative SARS-CoV-2 IgG lab-based serology test. The test measures levels of IgG Abs to help in the evaluation of a person’s immune response The study to determines the clinical performance of Abbott’s SARS-CoV-2 IgG II Quant test on its Alinity i instrument showed that it had 99.60% […]

  • Digital Diabetes Market to Reach $1.5B by 2024, Research Finds

    What You Should Know: – The digital diabetes market is on track to reach $1.5 billion dollars by 2024, according to a new report by Research2Guidance. – The confident growth of digital diabetes care will be driven by the growth of the global addressable market for digital diabetes services. Between 2019 and 2024, the number of diagnosed diabetics […]

  • PharmaShots Weekly Snapshot (Nov 30 – Dec 04, 2020)

    Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for $263.5M Published: Dec 3, 2020 | Tags: Asset Purchase Agreement, Evra, Gedeon Richter, Janssen Pharmaceutical, Signs, Transdermal Contraceptive Patch Assets, Treat Jazz Pharma and PharmaMar’s Zepzelca Fail to Meet its Primary Endpoint in P-III ATLANTIS Study for SCLC Published: Dec 3, 2020 | Tags: ATLANTIS, Doxorubicin, […]

  • Abbott’s FreeStyle Libre 2 Receives Health Canada’s Approval for Adults and Children with Diabetes

    Shots: Abbott’s next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received Health Canada’s approval for adults & children with diabetes The system continuously measures glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high/low without scanning The technology sustains performance for ~14days, providing trends, insights & actionable data […]

  • White House Coronavrius Task Force Doubles Down on Rapid Testing Strategy

    What You Should Know: – White house coronavirus task force doubles down on rapid testing strategy to fight the coronavirus as some states say they don’t have the supplies to comply with the federal government’s advice. – This article was originally published by the Center for Public Integrity, a nonprofit investigative news organization based in Washington, […]

  • PharmaShots Weekly Snapshots (Nov 09-13, 2020)

    Qiagen Launches Portable Digital SARS-CoV-2 Antigen Test in the US Published: Nov 13,2020 | Tags: Antigen Test, Digital, Launches, Portable, Qiagen, SARS-CoV-2, US GSK and Medicago Initiate P-II/III Study of its Plant-Derived COVID-19 Vaccine Published: Nov 13,2020 | Tags: COVID-19, GSK, Initiate, Medicago, P-II/III, Plant- Derived study, vaccine BD Acquires the Medical Business Assets of […]

  • Abbott Launches IonicRF Generator for Patients with Chronic Pain in the US

    Shots: Abbott has launched the IonicRF Generator, which is used to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system Radiofrequency ablation uses an electric current to heat up a small area of nerve tissue to stop it from sending pain signals. Studies showed that pain relief following a […]

  • PharmaShots Weekly Snapshot (Nov 02-06, 2020)

    AstraZeneca’s Brilinta (ticagrelor) Receives the US FDA’s Approval to Reduce the Risk of Stroke in Patients with an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Published: Nov 6, 2020 | Tags: AstraZeneca, Brilinta, ticagrelor, Receives, US FDA, Approval, Acute, High,Risk, Transient, Ischaemic, Stroke Novo Nordisk to Acquire Emisphere Technologies for $1.8B Published: Nov 6, […]

  • How Data-Driven Technology Holds The Promise of Better Outcomes for Vascular Patients

    Abbott recently released global research on vascular patient care, designed to shine a light on the vascular patient journey. The report called “Beyond Intervention” uncovers the universal challenges faced by physicians who deliver vascular care, their patients, and the hospital administrators who support them. It also explores how the right use of technology and data […]

  • Abbott to Launch its Cardiac Mapping Platform in Europe and Australia

    Shots: The company has received CE mark in EU and approval in Australia for its new EnSite X EP system which offers the option to navigate the cardiac anatomy in two different ways on one platform. The system can create a 3D model of the patient’s cardiac anatomy in real time and will enable physicians […]

  • Insights+: COVID-19 Healthcare News Monthly Updates – October 2020

    Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]

  • PharmaShots Weekly Snapshot (Oct 12-16, 2020)

    Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, Canada, health, Inherited Retinal Disease, Luxturna, Novartis, receives, voretigene neparvovec Galapagos & Servier’s GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis Published: Oct 15, […]

  • PharmaShots Weekly Snapshot (Aug 24 -28, 2020)

    1. Taysha Gene Therapies’ TSHA-101 Receives the US FDA’s Orphan Drug Designation and Rare Pediatric Disease Designation for GM2 Gangliosidosis Published: Aug 27, 2020 | Tags:  Taysha Gene Therapies, TSHA-101, Receives, US, FDA, Orphan Drug Designation, Rare Pediatric Disease Designation, GM2 Gangliosidosis 2. Bayer Reports the NDA Submission to NMPA for Vericiguat to Treat Chronic […]

  • COVID-19 Infects Patient & Practitioner Demands, Unsettling the Future of Hospital Operations

    Eric Stone, Co-Founder & CEO at Velano Vascular Prior to the outbreak of COVID-19, the healthcare industry in the United States was in the midst of an intense refocusing on patient-centered care. This evolution was defined by a number of innovations, policies, and even federal reimbursement programs that prioritized emphasis on and impact on the patient experience. It […]